| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
ML367 targets ATPase family AAA domain-containing protein 5 (ATAD5), a protein involved in DNA repair and replication stress responses. By inhibiting ATAD5 stabilization, ML367 disrupts the DNA damage response pathway, particularly affecting RPA32 and CHK1 phosphorylation.
|
|---|---|
| ln Vitro |
In HEK293T cells, ML367 (0–40 μM, 16 hours) decreases FLAG-ATAD5 stability whether 20 μM 5-FUrd is present or not[1].
In vitro, ML367 (0-40 µM, 16 h) inhibits FLAG-ATAD5 stabilization in HEK293T cells. It suppresses general DNA damage responses, including RPA32-phosphorylation and CHK1-phosphorylation, in response to UV irradiation. These activities confirm its role as a probe molecule that blocks DNA repair pathways upstream of ATAD5. |
| ln Vivo |
In vivo studies for ML367 are limited, as it is primarily used as a research tool for studying DNA repair mechanisms. Its ability to inhibit ATAD5 and disrupt DNA damage responses suggests potential utility in sensitizing tumors to DNA-damaging agents, but detailed in vivo efficacy data have not been widely published.
|
| Enzyme Assay |
The in vitro binding and activity of ML367 are typically assessed using cell-based assays rather than direct enzyme-receptor binding assays. The compound is tested for its ability to inhibit FLAG-ATAD5 stabilization in HEK293T cells. Cells are treated with ML367 (0-40 µM) for 16 hours, followed by immunoblotting to detect FLAG-ATAD5 levels. The inhibition of ATAD5 stabilization is quantified relative to untreated controls.
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: HEK293T cells Tested Concentrations: 0-40 μM in the presence or absence of 20 μM 5-Furd Incubation Duration: 16 hrs (hours) Experimental Results: Inhibition of 5-Furd-induced increase in ATAD5 protein levels. Cellular assays for ML367 involve treating HEK293T cells expressing FLAG-ATAD5 with varying concentrations of ML367 for 16 hours. The effect on ATAD5 stabilization is assessed by Western blot analysis using an anti-FLAG antibody. Additionally, the inhibition of RPA32 and CHK1 phosphorylation in response to UV irradiation is measured to evaluate the suppression of DNA damage responses. |
| Animal Protocol |
In vivo animal studies for ML367 are not well-documented in the public literature. As a probe molecule for DNA repair research, it may be evaluated in xenograft models to assess its ability to sensitize tumors to radiation or chemotherapy. However, specific in vivo protocols have not been standardized or widely reported.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of ML367 have not been extensively characterized. It is a small molecule with a molecular weight of 334.32 g/mol (free base) or 424.83 g/mol (as a salt) and solubility in DMSO (≥80 mg/mL). Further studies are needed to determine its bioavailability, half-life, and tissue distribution.
|
| Toxicity/Toxicokinetics |
Toxicity data for ML367 are limited. It is primarily used in research settings, and comprehensive toxicological evaluations have not been published. As with other DNA repair inhibitors, potential off-target effects and genotoxicity would need to be assessed in future studies.
|
| References | |
| Additional Infomation |
ML367 is a chemical probe developed for research purposes and has not entered clinical trials. It functions by blocking DNA repair pathways that operate upstream of ATAD5, making it a valuable tool for studying the role of ATAD5 in the DNA damage response. It may have potential applications in cancer research.
|
| Molecular Formula |
C19H12F2N4
|
|---|---|
| Molecular Weight |
334.322190284729
|
| Exact Mass |
334.103
|
| CAS # |
381168-77-0
|
| PubChem CID |
921541
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
4.2
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
25
|
| Complexity |
432
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC1=C(C=CC(=C1)NC1C2C=CC=CC=2N=C(C2C=CN=CC=2)N=1)F
|
| InChi Key |
LBPYNNJXARHGAG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H12F2N4/c20-15-6-5-13(11-16(15)21)23-19-14-3-1-2-4-17(14)24-18(25-19)12-7-9-22-10-8-12/h1-11H,(H,23,24,25)
|
| Chemical Name |
N-(3,4-difluorophenyl)-2-pyridin-4-ylquinazolin-4-amine
|
| Synonyms |
ML367 ML-367 ML 367
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 125 mg/mL (~373.89 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.22 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (6.22 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.22 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9911 mL | 14.9557 mL | 29.9115 mL | |
| 5 mM | 0.5982 mL | 2.9911 mL | 5.9823 mL | |
| 10 mM | 0.2991 mL | 1.4956 mL | 2.9911 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
